Skip to content

ORBIMED ADVISORS LLC Insider Trading -- Recent SEC Form 4 Transactions

ORBIMED ADVISORS LLC (CIK 1055951) reported 80 SEC Form 4 insider transactions across 19 companies over the past 18 months (most recent 2026-09-30). Recent activity: Buy ADRX (2.0M shares), Buy ADRX (10.7M shares), Buy ADRX (769,601 shares), Buy ADRX (564,187 shares), Buy ADRX (300,249 shares). Source: SEC Form 4.

DateCompanyRoleTypeSharesValue
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy2.0M$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy10.7M$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy769,601$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy564,187$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy300,249$5.1M
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy7.1M$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy1.3M$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy513,067$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy256,448$0
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy61,516$1.0M
2026-09-30ADARx Pharmaceuticals, Inc. (ADRX)DirectorBuy588,235$10.0M
2026-09-23Electra Therapeutics, Inc. (ETRA)DirectorBuy1.1M$0
2026-09-23Electra Therapeutics, Inc. (ETRA)DirectorBuy2.0M$0
2026-09-23Electra Therapeutics, Inc. (ETRA)DirectorBuy1.7M$0
2026-09-23Electra Therapeutics, Inc. (ETRA)DirectorBuy758,279$0
2026-09-23Electra Therapeutics, Inc. (ETRA)DirectorBuy1.0M$15.0M
2026-09-23Electra Therapeutics, Inc. (ETRA)DirectorBuy333,333$5.0M
2026-08-12BlossomHill Therapeutics, Inc. (BLSM)DirectorBuy1.0M$0
2026-08-12BlossomHill Therapeutics, Inc. (BLSM)DirectorBuy1.0M$0
2026-08-12BlossomHill Therapeutics, Inc. (BLSM)DirectorBuy625,000$10.0M
2026-08-11Braveheart Bio, Inc. (BRVE)DirectorBuy9.1M$0
2026-08-11Braveheart Bio, Inc. (BRVE)DirectorBuy1.7M$30.0M
2026-08-11Braveheart Bio, Inc. (BRVE)DirectorBuy273,333$4.9M
2026-07-29Scribe Therapeutics, Inc. (SCTX)DirectorBuy1.0M$15.0M
2026-07-29Scribe Therapeutics, Inc. (SCTX)DirectorBuy348,825$0

Source: SEC Form 4 filings · as of 2026-09-30